examine: cv end points
DESCRIPTION
EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome. EXAMINE: CV End Points. SAVOR-TIMI 53 Study: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications?. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/1.jpg)
![Page 2: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/2.jpg)
![Page 3: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/3.jpg)
![Page 4: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/4.jpg)
![Page 5: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/5.jpg)
EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes
and Acute Coronary Syndrome
![Page 6: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/6.jpg)
EXAMINE: CV End Points
![Page 7: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/7.jpg)
SAVOR-TIMI 53 Study: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone
or Added to Other Diabetes Medications?
![Page 8: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/8.jpg)
SAVOR-TIMI 53: CV End Points
![Page 9: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/9.jpg)
Safety End Points
![Page 10: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/10.jpg)
Clinical Implications
![Page 11: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/11.jpg)
CV Events With Rosiglitazone
![Page 12: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/12.jpg)
Global Cost of Diabetes
![Page 13: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/13.jpg)
Insights From SAVOR-TIMI 53
![Page 14: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/14.jpg)
DPP-4 Inhibitors
![Page 15: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/15.jpg)
Hypoglycemia: Impact on Quality of Life
![Page 16: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/16.jpg)
Take-Home Messages
![Page 17: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/17.jpg)
Abbreviations
![Page 18: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/18.jpg)
Abbreviations (cont)
![Page 19: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/19.jpg)
References
![Page 20: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/20.jpg)
References (cont)
![Page 21: EXAMINE: CV End Points](https://reader036.vdocument.in/reader036/viewer/2022062321/56812ca7550346895d915017/html5/thumbnails/21.jpg)
References (cont)